Section 2 of 6
Executive summary
6 evidence topics · 57 sources
Clinical benefits of Descartes-08
Burden of Generalized myasthenia gravis
Summary
- Incidence and prevalence: In a U.S. claims and electronic health records database, the diagnosed prevalence and incidence of myasthenia gravis (MG) in the United States in 2021 were 37.0 per 100,000 persons and 3.1 per 100,000 persons. In 2017 MarketScan data, the age- and sex-standardized incidence was 68.5 new cases per million person-years and the adjusted prevalence 316.4 per million in the commercially and Medicare-insured cohort, and 49.7 per million person-years and 203.7 per million in the Medicaid-insured cohort; the authors estimated approximately 82,715 U.S. adults living with MG in 2021 (320.2 cases per million adults). Among Medicare fee-for-service beneficiaries aged 65 years and older, incidence increased from 12.2 to 13.3 per 100,000 person-years from 2008–2009 to 2018–2019, and period prevalence from 81 to 119 per 100,000 from 2006–2007 to 2018–2019. The ICER budget impact inputs yielded 46,870 patients with generalized MG (gMG) in MGFA clinical classes II to IV.
- Generalized disease and antibody status: About 80% of patients progress to some form of generalized disease, typically within the first two years of symptom onset, and approximately 80% of patients with gMG have AChR autoantibodies. In 20% of patients with MG, weakness remains confined to the extraocular muscles. In a cohort of 220 participants diagnosed with gMG, 84% were anti-AChR positive, 6% anti-MuSK positive, and 10% seronegative.
- Myasthenic crisis and exacerbations: Myasthenic crisis, defined by respiratory insufficiency requiring invasive or non-invasive ventilation, occurs in approximately 15% to 20% of patients with MG, usually within the first 2 to 3 years of the disease, and mortality in U.S. cohorts is less than 5%. Approximately 20% of patients with gMG are estimated to experience a crisis over a period of 3 years or longer, and approximately one third experience myasthenic exacerbations within any given year. Among 16,561 gMG patients (12,813 prevalent and 3748 incident), exacerbation occurred during follow-up in 12.2% and 22.0% and myasthenic crisis in 6.0% and 12.4%. In one cohort, crisis occurred in 8.9% of individuals, with a 30-day mortality of 28.1%; 5-year overall survival was 75% overall and 39% among those with crisis.
- Hospitalization and mortality: Among 19,715 adult patients with 56,822 admissions, hospitalization rates increased from 2010 to 2019 at an average annualized rate of 4.9% (6.8% for MG crisis), readmission rates were approximately 20% in each year, and in-hospital mortality averaged 1.8% overall and 5.0% among patients aged 65 years or older. In another inpatient analysis, in-hospital mortality was 2.2% overall and 4.47% in MG crisis. Among Medicare fee-for-service beneficiaries aged 65 years and older with MG, all-cause mortality was 6.26 deaths per 100 person-years in 2006–2007 and 5.67 in 2018–2019 (p = 0.18). In a cohort of 6024 incident MG and 30,083 control beneficiaries, mortality was 66.8 versus 57.1 per 1000 person-years; after adjustment for time-varying comorbidity, the adjusted hazard ratio was 1.09 (0.87 to 1.36), and 16% of deaths in the MG cohort were attributed to MG.
- Symptoms and quality of life: In interviews with 28 individuals with gMG in the United States, participants reported an average of 16 symptoms; the most frequent were eyelid drooping (93%), physical fatigue (89%), and symptoms affecting the legs, difficulty breathing, and difficulty holding the head up (82% each). 96% reported fluctuations in symptoms and severity, and all reported emotional impacts and impacts on work and finances. Among 841 participants from seven countries, mean baseline EQ-5D-5L utility was 0.817, 0.766, 0.648, and 0.530 for MGFA classes I to IV. Among 1,859 respondents (58.4% with moderate-to-severe MG), mean EQ-5D-5L utility was 0.739 versus 0.843 in the POPUP comparison sample; 34.4% versus 13.2% of the general population reported sick leave in the past month, and 34.8% versus 8.3% reported needing help from a caregiver. In the MyRealWorld-MG study, 11.4% reported stopping work or retiring early due to MG, and patients with severe MG incurred 3.8 times more productivity losses than patients with mild disease.
- Economic burden: Among adults with newly diagnosed gMG in Komodo Research data (January 1, 2017, to September 30, 2023), mean annual all-cause total health care costs were $58,341 versus $14,469 in a non-MG cohort (difference $43,872), and 59.3% of the difference was driven by pharmacy costs, mostly immunoglobulin. Among 16,561 gMG patients, costs were $5420 per patient per month (about $65,000 per annum) versus $1298 (about $15,500 per annum) for non-gMG controls, and $17,113 and $18,640 per patient per month in patients with exacerbation and crisis. In matched cohorts of 2,739 patients each, mean incremental healthcare costs associated with MG were $4,155 ($5,567 versus $1,411), and mean monthly costs in the exacerbation or crisis subgroup (n = 419) were $17,330. Patients with a clinical event had mean total healthcare costs of $95,821 versus $25,029 for those without. All-cause costs were $173,956.99 in the 12 months after a crisis index date. The difference-in-difference estimates of total health care cost for an MG diagnosis were $25,799 in commercial and $4,927 in Medicare patients. Among 8833 patients with gMG, annual all-cause costs were $76,381 with any glucocorticoid use and $35,309 without. Median annual MG-related costs were $81,900 in a chronic IVIg cohort, $30,300 in a multiple nonsteroidal immunosuppressant cohort, and $2540 in the reference cohort. Among 800 people with MG and 238 caregivers, 70% reported making financial adjustments or seeking financial assistance, and annual out-of-pocket costs had a mean of $15,798 and a median of $7750.
Descartes-08 efficacy and safety
Summary: phase 2b efficacy and safety
In the phase 2b, randomized, double-blind, placebo-controlled portion of MG-001, 36 participants were randomized to Descartes-08 (n = 20) or placebo (n = 16), comprising the safety population. The primary efficacy population was a modified intention-to-treat population of 26 participants enrolled at an academic medical center with at least one postinfusion follow-up (Descartes-08 n = 15; placebo n = 11). The primary endpoint, a decrease of 5 points or more in the MGC score at month 3, was met in 10 of 15 participants (66.7%) receiving Descartes-08 and 3 of 11 (27.3%) receiving placebo (difference in proportions 0.39, 95% CI 0.01 to 0.77; P = 0.0472). In the anti-AChR antibody-positive subpopulation, the proportions were 63.6% (7/11) and 12.5% (1/8) (P = 0.0258). The company's 2024 topline release reported 71% (10/14) and 25% (3/12) in its pre-specified mITT efficacy population (p=0.018).
At month 3, mean changes from baseline in the mITT population were −5.0 versus −2.3 for MGC, −4.1 versus −1.6 for MG-ADL, −3.9 versus −1.5 for QMG, and −5.7 versus −3.7 for MG-QoL-15r. These secondary comparisons did not meet the hierarchical threshold for formal testing, and the authors attribute the lack of statistical significance in secondary outcomes to placebo responses during early follow-up. All 11 placebo participants received open-label Descartes-08 after month 3. In the Descartes-08 group, the mean (s.d.) MG-ADL reduction was −5.5 (1.1) at month 4 and −4.8 (1.4) at month 12, and the QMG reduction was −6.0 (2.1) at month 12. The share of participants with a sustained clinically meaningful response at month 12 is reported as 83.0% in the abstract and 80.0% in the Discussion; the company's April 2025 release reported 83% (10/12) of evaluable participants, defined as an MG-ADL reduction of at least 2 points. Minimum symptom expression (MG-ADL score of 1 or less) was reached by 33.3% (4/12) of Descartes-08 participants who reached month 6 and was maintained through month 12 (33.0% in the abstract). The median daily prednisone-equivalent dose in the Descartes-08 group was 9 mg at a median follow-up of 12 months, compared with 20 mg at baseline, and no participant randomized to Descartes-08 required escalation of MG therapy.
In the safety population, 17 of 20 participants (85.0%) receiving Descartes-08 and 13 of 16 (81.3%) receiving placebo reported at least one adverse event during the study, serious adverse events occurred in 5 (25.0%) and 3 (18.8%), and grade 3 adverse events in 5 (25.0%) and 2 (12.5%) participants; no grade 4 or 5 events occurred in either group for the duration of the study. The only treatment-related serious adverse event was a grade 3 infusion-related reaction with a fever of 40 °C after the fifth infusion, which resolved within 48 h without tocilizumab or steroids. Infusion-related reactions occurred in 16 (80.0%) and 9 (56.3%) participants, fever in 11 (55.0%) and 1 (6.3%), and chills in 12 (60.0%) and 0. Herpes simplex virus reactivation occurred in 3 (15.0%) and 0 participants, all with a prior history of labial herpes and on concomitant azathioprine. No case of hypogammaglobulinemia was reported. The company's April 2025 release reported no Descartes-08-related adverse events from month 4 through month 12 and no cases of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.
Summary: phase 1b/2a and long-term follow-up
The phase 1b/2a portion of MG-001 was a prospective, open-label, multicenter, nonrandomized study in which 14 participants were enrolled (3 in Part 1 and 11 in Part 2); its primary endpoints were tolerability in Part 1 and safety in Part 2. There was no dose-limiting toxicity, cytokine release syndrome, or neurotoxicity, and 52.5 × 10⁶ CAR+ cells/kg was the maximum tolerated dose. One serious adverse event in Part 1 (grade 2 influenza after apheresis and before treatment) was unrelated to Descartes-08. Two serious adverse events occurred in Part 2: grade 3 urticaria after the third infusion, deemed possibly related and resolved after intravenous steroids, and a non-ST segment elevation myocardial infarction 72 hours after the sixth infusion in an 83-year-old man, deemed unrelated. Headache, fever, and nausea were the most common treatment-related adverse events in Part 2, in 5 (45%), 4 (36%), and 4 (36%) participants. Across 14 participants and 88 infusions, no anaphylaxis, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or hematologic toxicity was reported.
Among the 9 Part 2 participants in the twice-weekly and weekly arms with 12-week follow-up, mean (95% CI) changes at week 12 were −5·9 (−9 to −2·8) for MG-ADL, −7 (−11 to −3) for QMG, −14 (−19 to −9) for MGC, and −9 (−15 to −3) for MG-QoL-15r. All 7 participants in the weekly-dosing arm completed 12 months of follow-up. At month 9, their mean MG-ADL change was −6.3 (95% CI −3.5 to −9.1) and their mean MGC change −16.6. At month 12, 5 of the 7 participants maintained clinically meaningful improvement, with a mean MG-ADL change of −4.6 (95% CI −8.8 to −0.4) and a mean MGC change of −11.3 (−18.0 to −4.6). Among the 5 weekly-arm participants receiving prednisone at baseline, the median daily dose decreased from 17.5 mg to 5 mg by month 12, and neither of the 2 participants receiving IVIg at baseline required it during follow-up. No new product-related adverse events were reported during the 12-month follow-up.
Three weekly-arm participants were retreated after worsening (two at month 12 and one at month 18); two reached minimum symptom expression by week 8 and maintained it through 12 months after retreatment. In a company-reported pooled case series of 5 participants from the phase 2a and phase 2b portions (2026), the mean MG-ADL reduction from baseline at month 12 after retreatment was 6.6 (±4.2) points and the mean MGC reduction 15 (±6.2) points; no serious adverse events occurred during retreatment, and infusion-related reactions occurred with 17 of 30 retreatment infusions and 16 of 30 initial infusions.
Summary: AURORA phase 3 status
AURORA is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial comparing Descartes-08 with placebo (1:1 randomization), administered as six once-weekly outpatient infusions without preconditioning chemotherapy, in adults with acetylcholine receptor autoantibody-positive generalized myasthenia gravis. The primary endpoint is the proportion of participants with an MG-ADL improvement of 3 points or more at month 4 compared with placebo; secondary endpoints include an MGC reduction of 4 points or more, QMG, MG-QoL-15r, and safety. The company states planned enrollment of approximately 100 participants; the registry record (last update posted 2026-09-01) lists actual enrollment of 128, a status of active and not recruiting, and estimated primary completion on 2026-12-30. The FDA reached written agreement on the overall trial design under the Special Protocol Assessment process in January 2025. The company expects a data readout in the first quarter of 2027 and plans a biologics license application in mid-2027; it has no products approved for sale.
Budget impact of Descartes-08
Summary
The report holds no budget impact model and no announced price for Descartes-08; the company states that it has no products approved for sale and has not generated any product sales. The inputs a model would draw on are quoted elsewhere in the report:
- Eligible population: ICER's 2021 budget impact analysis estimated 46,870 U.S. patients with gMG (MGFA clinical classification II to IV), assumed that 100% would be diagnosed, and assumed that 20% would initiate the new treatment in each of five years (9,374 additional patients per year). ICER states that approximately 80% of patients with generalized MG have AChR autoantibodies; a November 2026 company presentation gives a share of about 85% with AChR antibodies, citing Lazaridis et al., 2020, and AURORA is designed for participants with AChR antibody-positive MG. The company estimates that MG affects over 106,000 patients in the U.S., and a study of MarketScan databases estimated approximately 82,715 U.S. adults living with MG in 2021. Among 782 participants in a survey study, 49 (6%) had refractory gMG at enrollment and 201 (26%) were classified as ever-refractory. Among 8759 adults with gMG in Komodo Research Data, use of C5 inhibitors rose from 0.3% to 3.4% and of FcRn blockers from 0.3% to 3.8% between the first and fifth treatment episodes.
- Dosing: AURORA administers Descartes-08 as six once-weekly infusions without preconditioning chemotherapy, and the company describes it as designed for outpatient administration. A company presentation cites projections “inclusive of opportunity to retreat patients”.
- Comparator costs: wholesale acquisition costs of $6,314.19 per vial of Vyvgart (2 or 3 vials per dose, weight based) as of September 30, 2025, $16,410.23 per vial and $17,066.64 per syringe of Vyvgart Hytrulo (1 per dose) as of October 1, 2026, and $140,248.50 per dose of Uplizna (2025); a price of $6,523 per single-dose vial of Soliris (2025). One study estimated the annual cost of health-care-provider-administered gMG treatment at $223,272 to $648,960 depending on drug and body weight.
- Cell therapy costs: among 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma, the median cost of CAR-T products was $402 500 and median total costs $608 100. Across 391 Medicare CAR-T claims, the average Medicare cost was US$498,723 in the inpatient setting and $414,393 in the outpatient setting. CMS pays an inpatient CAR-T case through a single DRG payment for the stay and a solely outpatient case at Average Sales Price plus 6%; in the FY 2027 final rule, CMS estimated average costs of $410,125 for nonclinical trial cases assigned to MS-DRG 018. Costs of cilta-cel therapy excluding product acquisition were estimated at US$160,933 over 12 months, including $18,268 in pre-infusion costs such as apheresis.
- Budget thresholds in prior ICER assessments: 8.8% of the eligible gMG population could be treated with efgartigimod at its placeholder price without passing ICER's budget impact threshold, and 43% of eligible multiple myeloma patients could be treated with ide-cel at its list price of $419,500 within five years before crossing the threshold of $819 million per year.
Conclusions
Summary
Descartes-08 holds FDA Orphan Drug Designation for myasthenia gravis (dated 11/08/2022) and Regenerative Medicine Advanced Therapy designation (May 2024), and the FDA agreed to the design of the phase 3 AURORA trial under a Special Protocol Assessment in January 2025; the registry lists actual AURORA enrollment of 128 participants (the company planned approximately 100), the company expects topline data in the first quarter of 2027 and a biologics license application in mid-2027, and it has no products approved for sale. In the phase 2b portion of MG-001, an MGC improvement of 5 points or more at month 3 occurred in 10 of 15 participants (66.7%) receiving Descartes-08 and 3 of 11 (27.3%) receiving placebo (P = 0.0472) in a primary efficacy population of 26 of the 36 randomized participants, and the mean MG-ADL reduction in the Descartes-08 group was −4.8 at month 12, after all 11 placebo participants had received open-label Descartes-08 following month 3. During the study, adverse events occurred in 17 of 20 (85.0%) and 13 of 16 (81.3%) participants and infusion-related reactions in 16 (80.0%) and 9 (56.3%), the only treatment-related serious adverse event was a grade 3 infusion-related reaction, and no anaphylaxis was reported across 14 participants and 88 infusions in the earlier phase 1b/2a portion. The phase 2b results are limited by the sample size, a change of the primary endpoint from the MG-ADL score to the MGC score after 44 participants had enrolled and before unblinding, imbalance in disease duration and thymoma between groups, secondary comparisons that did not meet the threshold for formal testing, and infusion-related reactions that may have affected assessment of severity scales. A 2026 guidance statement advises clinicians to initiate targeted therapies when conventional therapy does not achieve symptom control within 6 to 12 months, the company states that complement and FcRn agents are typically administered continually and that Descartes-08 is designed for outpatient administration without preconditioning chemotherapy, and a 2026 article states that, at present, CAR-T therapy “should be considered experimental and delivered in specialised centres, pending longer term safety and durability data”. The report holds no price, budget impact model, or cost-effectiveness analysis for Descartes-08; comparator evidence includes a 2022 analysis in which the incremental cost-effectiveness ratio was never less than $3.8 million per QALY/evLYG for eculizumab and $1.7 million per QALY/evLYG for efgartigimod, and CAR-T cost evidence includes B-cell lymphoma and systemic lupus erythematosus settings.